대한방사성의약품학회지 (Journal of Radiopharmaceuticals and Molecular Probes)

  • 제7권1호
  • /
  • Pages.3-10
  • /
  • 2021
  • /
  • 2384-1583(pISSN)
  • /
  • 2508-3848(eISSN)
대한방사성의약품학회 (Korean Society of Radiopharmaceuticals and Molecular Probes)
권호 표지
DOI QR코드

DOI QR Code

Preliminary research on the development of boron neutron capture therapy drugs

  • Soyeon Kim (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Ji-ung Yang (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Kyo Chul Lee (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Jung Young Kim (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Yong Jin Lee (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Ji-Ae Park (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS))
  • 투고 : 2021.06.11
  • 심사 : 2021.06.28
  • 발행 : 2021.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

For successful boron neutron caputre therapy, it is essential to develop a boron drug with a selective accumulation capacity for tumors. In particular, in order to apply boron neutron caputre therapy to brain tumors, drugs with good blood-brain barrier penetration are required. In this study, two low-molecular-weight boron compounds were introduced as brain tumor boron neutron caputre therapy drugs, and their physical and biological efficacy were evaluated. Among them, B2 showed good blood-brain barrier permeability and a high brain/blood ratio. From these results, it is expected that B2 can be used as a useful boron drug for boron neutron caputre therapy in brain tumors.

키워드

과제정보

이 논문은 한국연구재단 중견연구자지원사업(2020R1A2C200790611)과 과학기술정보통신부 한국원자력의학원 연구운영비지원사업(50532-2021)의 지원에 의하여 이루어졌으며 다른 이해관계는 없음을 밝힙니다.

참고문헌

  1. Sauerwein WA. Principles and roots of neutron capture therapy. In: Sauerwein WA, Wittig A, Moss R, Nakagawa Y, editors. Neutron Capture Therapy. New York : Springer-Verlag; 2012. p. 1-3.
  2. Brugger RM, Shih JA. Evaluation of gadolinium-157 as a neutron capture therapy agent. Strahlenther Onkol 1989;165:153-6.
  3. Barth RF, Coderre JA, Vicente MG, Blue TE. Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 2005;11(11):3987-4002. https://doi.org/10.1158/1078-0432.CCR-05-0035
  4. Barth RF, Mi P, Yang W. Boron delivery agents for neutron capture therapy of cancer. Cancer Commun 2018;38(1):35.
  5. Capala J, Stenstam BH, Skold K, Rosenschold PM, Giusti V, Persson C, Wallin E, Brun A, Franzen L, Carlsson J, Salford L, Ceberg C, Persson B, Pellettieri L, Henriksson R. Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden. J Neuro-Oncol 2003;62(1-2):135-44.
  6. Barth RF, Soloway AH, Fairchild RG, Brugger RM. Boron neutron capture therapy for cancer. Realities and prospects. Cancer 1992;70(12):2995-3007. https://doi.org/10.1002/1097-0142(19921215)70:12<2995::AID-CNCR2820701243>3.0.CO;2-#
  7. Mishima Y, Honda C, Ichihashi M, Obara H, Hiratsuka J, Fukuda H, Karashima H, Kobayashi T, Kanda K, Yoshino K. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound. Lancet 1989;2(8659):388-9.
  8. Sauerwein WA, Bet PM, Wittig A. Drugs for BNCT: BSH and BPA. In: Sauerwein WA, Wittig A, Moss R, Nakagawa Y, editors. Neutron Capture Therapy. Berlin : Springer-Verlag; 2012. p. 117-160.
  9. Soloway AH, Tjarks W, Barnum BA, Rong FG, Barth RF, Codogni IM, Wilson JG. The Chemistry of Neutron Capture Therapy. Chem Rev 1998;98(4):1515-62. https://doi.org/10.1021/cr941195u
  10. Salt C, Lennox AJ, Takagaki M, Maguire JA, Hosmane NS. Boron and gadolinium neutron capture therapy. Russ Chem Bull 2004;53(9):1871-88.
  11. Yanagie H, Ogata A, Sugiyama H, Eriguchi M, Takamoto S, Takahashi H. Application of drug delivery system to boron neutron capture therapy for cancer. Expert Opin Drug Deliv 2008;5(4):427-43. https://doi.org/10.1517/17425247.5.4.427
  12. Hawthorne MF. The role of chemistry in the development of boron neutron capture therapy of cancer. Angew Chem Int Ed 1993;32(7):950-84. https://doi.org/10.1002/anie.199309501
  13. Futamura G, Kawabata S, Nonoguchi N, Hiramatsu R, Toho T, Tanaka H, Masunaga SI, Hattori Y, Kirihata M, Ono K, Kuroiwa T, Miyatake SI. Evaluation of a novel sodium borocaptate-containing unnatural amino acid as a boron delivery agent for neutron capture therapy of the F98 rat glioma. Radiat Oncol 2017;12(1):26.
  14. Cerecetto H, Couto M. Medicinal chemistry of boron-bearing compounds for BNCT-glioma treatment: Current challenges and perspectives. In: Omerhodzic I, Arnautovic K, editors. Glioma: Contemporary Diagnostic and Therapeutic Approaches. London : Intech Open; 2018. p. 205-230.
  15. Ishiwata K. 4-Borono-2-18F-fluoro-l-phenylalanine PET for boron neutron capture therapy-oriented diagnosis: Overview of a quarter century of research. Ann nucl med 2019;33(4):223-36. https://doi.org/10.1007/s12149-019-01347-8
  16. Uzuegbunam BC, Librizzi D, Yousefi BH. PET radiopharmaceuticals for Alzheimer's disease and Parkinson's disease diagnosis, the current and future landscape. Molecules. 2020;25(4):977.
  17. Bradshaw TD, Westwell AD. The development of the antitumour benzothiazole prodrug, phortress, as a clinical candidate. Curr Med Chem. 2004;11(8):1009-21. https://doi.org/10.2174/0929867043455530
  18. Perepechaeva ML, Grishanova. The role of aryl hydrocarbon receptor (AhR) in brain tumors. Int J Mol Sci 2020;21(8):2863.
  19. Pathan SA, Iqbal Z, Zaidi SMA, Talegaonkar S, Vohra D, Jain GK, Azeem A, Jain N, Lalani JR, Khar RK, Ahmad FJ. CNS drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul 2009;3(1):71-89. https://doi.org/10.2174/187221109787158355
  20. Hall DG. Boronic acid catalysis. Chem Soc Rev 2019;48(13):3475-96. https://doi.org/10.1039/C9CS00191C
  21. Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, Kirihata M, Nakazawa M, Yura Y. Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot 2004;61(5):1069-73. https://doi.org/10.1016/j.apradiso.2004.05.059
  22. Balcerzyk M, De-Miguel M, Guerrero C, Fernandez B. Quantification of Boron Compound Concentration for BNCT Using Positron Emission Tomography. Cells 2020;9(9):2084.
  23. Pignol JP, Oudart H, Chauvel P, Sauerwein W, Gabel D, Prevot G. Selective delivery of 10B to soft tissue sarcoma using 10B-L-borophenylalanine for boron neutron capture therapy. Brit J Radiol 1998;71(843):320-3. https://doi.org/10.1259/bjr.71.843.9616243
  24. Yokoyama K, Miyatake SI, Kajimoto Y, Kawabata S, Doi A, Yoshida T, Asano T, Kirihata M, Ono K, Kuroiwa T. Pharmacokinetic study of BSH and BPA in simultaneous use for BNCT. J Neuro-Oncol 2006;78(3):227-32. https://doi.org/10.1007/s11060-005-9099-4
  25. Wittig A, Huiskamp R, Moss RL, Bet P, Kriegeskotte C, Scherag A, Hilken G, Sauerwein WAG. Biodistribution of 10B for Boron Neutron Capture Therapy (BNCT) in a Mouse Model af ter In jection of Sodiu m Mercaptoundecahydro-closo-dodecaborate and l-para-Boronophenylalanine. Radiat Res 2009;172(4):493-9. https://doi.org/10.1667/RR1700.1
  26. Joel DD, Coderre JA, Micca PL, Nawrocky MM. Effect of dose and infusion time on the delivery of p-boronophenylalanine for neutron capture therapy. J Neuro-Oncol 1999;41(3):213-21. https://doi.org/10.1023/A:1006176901713